Nachrichten zur BioCryst Pharmaceuticals Aktie

Biocryst Pharmaceuticals, Biolase among healthcare movers

…

: Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Shares of Pharvaris N.V. PHVS jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its…

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Launches ORLADEYO® (berotralstat) in Spain

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced updates…

BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2023.…

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript

…

BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stocks Bear Run

…

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment…

BioCryst to Host R&D Day on November 3

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst to Report Third Quarter 2023 Financial Results on November 2

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst upgraded to buy at Jefferies on undervaluation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call Transcript

BCRX earnings call for the period ending June 30, 2023....…

BioCryst Pharmaceuticals Non-GAAP EPS of -$0.24 misses by $0.03, revenue of $82.49M beats by $1.06M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst to Report Second Quarter 2023 Financial Results on August 3

RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst signs agreement with Er-Kim Pharmaceuticals to commercialise ORLADEYO in Turkey.

ORLADEYO (berotralstat) is claimed to be the first and only oral treatment intended particularly to prevent attacks of hereditary angioedema (HAE)…

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company…

BioCryst gains as Bank of America upgrades citing recent pullback

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K BIOCRYST PHARMACEUTICALS For: Jul 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that…

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst gains 14% most since February after Q1 2023 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript

BCRX earnings call for the period ending March 31, 2023....…

Why BioCryst Pharmaceuticals Stock Is Soaring Today

The biotechs Q1 earnings report contained a number of positives....…

BioCryst Clocks 37.8% Revenue Growth In Q1 On Solid New Patient Growth

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million—...…

BioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Pharmaceuticals Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst to Report First Quarter 2023 Financial Results on May 3

RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

IN BRIEF: BioPharma Credit invests in BioCryst of up to USD180 million

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst secures five-year credit facility

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the…

Form 8-K BIOCRYST PHARMACEUTICALS For: Mar 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioCryst wins Canadian nod for Orladeyo reimbursement

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Shares of BioCryst Pharmaceuticals Jumped Today

A day after the stock plummeted, it bounced back....…

BioCryst adds 13% to rebound as Needham upgrades; says selloff overdone

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Opening Bell: Nasdaq 100, Dow Jones, Walmart, Palo Alto, Palantir, Coinbase, JD.com, PDD, BioCryst

Die Wall Street startete erst gestern in die neue Handelswoche. Und es war ein verhaltener Start. Der Dow Jones gab…

Opening Bell: Wall Street startet nach Vortagesverlusten freundlich; Fed-Protokoll, Walmart, JD.com, Palo Alto Networks, Palantir, Biocryst, PDD Holdings im Fokus

Die US-Börsen dürften am Mittwoch einen Stabilisierungsversuch starten. Der Dow Jones notiert 30 Minuten vor dem Handelsstart bei 33.182 Punkten,…

dpa-AFX ProFeed